Drug Profile
Acalisib
Alternative Names: CAL-120; GS-9820Latest Information Update: 14 Feb 2017
Price :
$50
*
At a glance
- Originator Calistoga Pharmaceuticals
- Developer Gilead Sciences
- Class Purines; Quinazolinones; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia; Lymphoma
- Discontinued Solid tumours
Most Recent Events
- 03 Dec 2016 Gilead Sciences presented pharmacodynamics and safety data from preclinical studies in Lymphoma and Chronic lymphocytic leukaemia at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH)
- 01 May 2016 Gilead Sciences completes a phase I trial in Chronic lymphocytic leukaemia and lymphoma in Netherlands (PO) (NCT01705847)
- 14 May 2014 Gilead Sciences completes enrolment in its phase Ib trial for Lymphoma & Chronic lymphocytic leukaemia in Netherlands (NCT01705847)